New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 22, 2014
08:02 EDTMYLMylan launches first generic Klor-Con Extended-release tablets
Mylan announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq and 10 mEq, which is the generic version of Upsher-Smith's Klor-Con. Mylan received final approval from the FDA for its Abbreviated New Drug Application, or ANDA, for this product, which is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. Mylan has begun shipping this product. Currently, Mylan has 294 ANDAs pending FDA approval representing $105.7B in annual brand sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $25B in annual brand sales, for the 12 months ending Dec. 31, 2013, according to IMS Health.
News For MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
13:01 EDTMYLOptions with increasing volume
Subscribe for More Information
10:46 EDTMYLOptions with increasing implied volatility
Subscribe for More Information
10:24 EDTMYLMylan volatility up after filing to sell 35M shares for Abbott Laboratories
Subscribe for More Information
09:27 EDTMYLOn The Fly: Pre-market Movers
Subscribe for More Information
09:15 EDTMYLTeva does not rule out bigger deal if opportunity arises
Subscribe for More Information
09:02 EDTMYLMylan slips amid Abbott share sale, Teva deal for Auspex
Subscribe for More Information
06:34 EDTMYLMylan files to sell 35M shares of stock for Abbott Laboratories subsidiaries
Subscribe for More Information
March 27, 2015
07:45 EDTMYLFDA to hold a public meeting
Subscribe for More Information
07:25 EDTMYLTeva appears to be weighing transformative deal, says Bernstein
After attending Teva's (TEVA) meeting with investors, Bernstein thinks that the company is considering making a 'transformative' acquisition, although it believes that such a deal may not be imminent. The firm sees Mylan ((MYL) and the generic units of Actavis (ACT), Pfizer (PFE), and possibly Valeant (VRX) as the four logical candidates. It says that Teva can pay $81 per share for Mylan, and that a takeover of Mylan would raise Teva's EPS to about $6.50 in 2017 and $7 in 2018. Bernstein raised its price target on Teva to $69 from $60 and keeps an Outperform rating on the shares.
March 17, 2015
08:34 EDTMYLInSite Vision announces settlement of lawsuit against Mylan
Subscribe for More Information
March 16, 2015
10:28 EDTMYLOptions with increasing implied volatility
Options with increasing implied volatility: PVA NFLX BMRN DNOW MYL TEVA PEP GE

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use